Cargando…
A case report of a patient with inoperable primary diffuse leptomeningeal melanomatosis treated with whole-brain radiotherapy and pembrolizumab
RATIONALE: Primary diffuse leptomeningeal melanomatosis (PDLM) is a rare disease that affects melanocytes in the leptomeninges. There is very limited data on the efficacy of immunotherapy in this setting. PATIENT CONCERNS: A patient (23 years old) was diagnosed with PDLM. Histologically, atypical me...
Autores principales: | Palacka, Patrik, Slopovsky, Jan, Makovnik, Marek, Kajo, Karol, Obertova, Jana, Mego, Michal |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8772673/ https://www.ncbi.nlm.nih.gov/pubmed/35060532 http://dx.doi.org/10.1097/MD.0000000000028613 |
Ejemplares similares
-
Primary leptomeningeal melanomatosis successfully treated with PD-1 inhibitor pembrolizumab: A case report
por: Misir Krpan, Ana, et al.
Publicado: (2020) -
Primary Intracranial Leptomeningeal Melanomatosis
por: Kim, Do-Hyoung, et al.
Publicado: (2015) -
Nonsyndromic Primary Diffuse Leptomeningeal Melanomatosis in a Child
por: TAVANA RAD, Salim, et al.
Publicado: (2021) -
Pediatric primary diffuse leptomeningeal melanomatosis: Case report and review of the literature
por: Xu, Xinke, et al.
Publicado: (2020) -
Novel Insights into Diagnosis, Biology, and Treatment of Primary Diffuse Leptomeningeal Melanomatosis
por: Baumgartner, Alicia, et al.
Publicado: (2021)